A clozapine's uncharted voyage: Five years and a pandemic after the end of mandatory haematological notifications to the Spanish medicines agency

Here we go again! Subtyping diagnosis and refining treatments

“…Stopping the compulsory reporting of the periodic hematological controls might yield a negative impact in the performance of blood controls and in the early detection of clozapine-related hematological alterations. 11 Moreover, there are certain clinical situations where these controls should be further increased. For instance, clozapine levels should be closely monitored and dose reduction may be contemplated to avoid toxicity when patients on clozapine present a systemic inflammation, either caused by an infection such as COVID-19 or due to a non-infectious cause.…”